Compare Harmony Gold Mining Co. (HMY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs ResMed Inc. — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 3.2× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (4.63%). Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and ResMed Inc. for 51 Days on average.
| HMY | RMD | |
|---|---|---|
Market Cap | $10.02B | $31.89B |
Volume | 3,643,683 | 618,314 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $275.96 |
52-Week Low | $13.32 | $182.82 |
Typical Hold Time | 45 Days | 51 Days |
Enterprise Value | $10.07B | $31.24B |
Dividend Yield | 4.63% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.84, up 2.12% today, while showing strong fundamental performance with record revenue of $73.90B in 2025 and net income of $14.38B. The stock exhibits bearish technical signals with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent earnings show mixed results with two beats and two misses in the last four quarters, while analyst consensus remains cautious with 70% hold ratings.
HMY presents a value opportunity with attractive valuation multiples (P/E 6.02, EV/EBITDA 3.54) and robust profitability metrics (ROE 46.23%, net margin 29.57%). However, investors face risks from the company's significant capital expenditure plans and gold price volatility. The transition to copper production offers long-term growth potential but requires careful monitoring of execution and market conditions.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
